Introducing Ingelvac Provenza™—the birth of a new generation in swine protection.
A new vaccine for pigs offers increased protection against damaging influenza strains that affect more than 70 percent of growing pigs every year
DULUTH, Ga. (March 5, 2018) — A new product on the market makes it possible to vaccinate pigs as young as day one against the serious influenza A virus in swine (IAV-S). With demonstrated efficacy and safety1, as well as the flexibility of timing and method of administration, Ingelvac Provenza™ fills an unmet need in the swine industry, and will establish a new way of thinking about influenza protection.
According to Dr. Christa Goodell, DVM, MS, PhD, Dipl ACVPM, Technical Manager for the Boehringer Ingelheim U.S. Swine Business, “Vaccinating pigs as young as 1 day old provides protection before pigs are most vulnerable.”3 Administered intranasally, Ingelvac Provenza™ provides a direct means of protection at the site of natural IAV-S infection.4,5
Developed and sold by Boehringer Ingelheim, Ingelvac Provenza™ is the first live attenuated influenza vaccine (LAIV) for growing pigs, offering a new level of protection against the threat of influenza virus strains H1N2 AND H3N21. Live attenuated influenza vaccine has been evaluated to reduce virus shedding in the presence of maternal antibodies.6
“Providing game-changing protection when it’s most needed, Ingelvac Provenza™ offers cross-protection against multiple IAV-S strains and decreases nasal shedding, thereby reducing transmission within the population,"1 added Goodell.
Del Birkhofer, Head of the U.S. Swine Business and Newport Laboratories, explained this ongoing threat, “IAV-S can have a widespread impact on the health of the pig population and subsequently, the productivity and profitability for producers. Studies have shown that uncomplicated IAV-S infection can lead to an estimated loss of more than $3 per pig, and when IAV-S is present with concurrent infections, the loss can be greater than $10 per pig.”2
Boehringer Ingelheim is a company committed to swine health and customer success, bringing innovative health solutions to veterinarians and producers across the United States.
For more information on Ingelvac Provenza™ visit IngelvacProvenza.com.
References
1. BIAH studies #2013200, 2013232, and 2014001 published on http://productdata.aphis.usda.gov.
2. Dykhuis Haden C, Painter T, Fangman T, Holtkamp D. Assessing production parameters and economic impact of swine in influenza, PRRS and Mycoplasma hyopneumoniae on finishing pigs in a large production system. In: Proceedings of the 43rd American Association of Swine Veterinarians Annual Meeting; March 10–13, 2012; Denver, CO: 75–76.
3. Alvarez J, Sarradell J, Kerkaert B, et al. Association of the presence of influenza A virus and porcine reproductive and respiratory syndrome virus in sow farms with post-weaning mortality. Prev Vet Med. 2015;121:240–245.
4. Vincent AL, Ma W, Lager KM, et al. Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine. 2007;25:7999–8009.
5. Janke BH. Influenza A virus infections in swine: pathogenesis and diagnosis. Vet Pathol. 2014;51:410–426.
6. Genzow M, Goodell C, Kaiser TJ, Johnson W, Eichmeyer M. Live attenuated influenza virus vaccine reduces virus shedding of newborn piglets in the presence of maternal antibody. Influenza Other Respir Viruses. 2017;00:1–7. doi:10.1111/irv.12531